ERYTECH will present a new vesiculation approach at the 24

ERYTECH to present New approach to vesiculation
at the 24thand Mmeeting of the European Society of Red Blood Cells

  • Oral presentation retailer the feasibility to produce loaded goods extracellular vesicles derivative from red blood cellss charged by the ERYCAPS® process, ERYCEVMT

Cambridge, MA (USA) and Lyons (France), April 04, 2022 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinic Stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells (RBC)today announcement the presentation of its new red blood cell vesiculation technology at the 24th Meeting the European Red Blood Cell Society (ERCS), To take place from April 7 to 11, 2022 at Gazzada Schiannotoh, Italianthere.

Oral presentation: Evaluation of production methods, characterization and biological activity of red blood cell-derived extracellular vesicles (RBCEV) containing active molecules.

Date hour: Saturday, April 9 at 11:30 a.m. local time during the session “Technology: red blood cells as carriers, cultured red blood cells, blood bank

Extracellular vesicles derived from red blood cells form naturally during senescence and storage of mature red blood cells. They are a potentially attractive drug delivery system due to their intrinsic properties: small size, wide range of potential delivery routes, natural targeting of immune cells, lack of nucleic acids, and readily available supply of red blood cells for their production. The vesiculation of red blood cells which have already been loaded with active therapeutic compounds using the ERYCAPS® process, implies the possibility of producing extracellular vesicles derived from red blood cells loaded with cargo for the development of new therapeutic approaches.

Françoise Horand, Director of R&D Operations at ERYTECHcommented: We are delighted for gift the work of our team and our collaborators during the next ERCS meeting, including the opportunity to introduce the ERYCEVMT Technology, which takes advantage of our owner ERYCAPS® technology in a novel fashionand makes it possible to produce extracellular vesicles derived from red blood cells, loaded with active ingredients. We are encouraged by the first results characterizing in vitro the biological activity of these preloaded RBCEVs, suggesting a potential future application in immune modulation.

Gil Beyen, CEO from ERYTECHadded: “The results it will be presented at the next ERCS conference point out the oppositeIbed and great potential of our ERYCAPS® platform. We look forward to discussing other potential development opportunities with the red blood cell community and will seek to provide updates on ERYCEV MT as the program progresses go forward.”

ERYTECH and its researchers will also participate in the Poster session on April 8 to present the Capabilities of the RBC ERYCAPS® Therapeutic Platformand in the “Erythrocyte diseases» session of April 10 to present the work carried out with the LIBM academic laboratory (Interuniversity Laboratory of Biology of Motricity of Lyon).

About ERYTECH and eryaspase (GRASPA®)

ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies based on red blood cells for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses novel technology to encapsulate drug substances within red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH is primarily focused on the development of product candidates that target the altered metabolism of cancer cells by depriving them of the amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated in donor red blood cells, targets the impaired asparagine and glutamine metabolism of cancer cells. Proof of concept of eryaspase as a cancer metabolism agent has been established in different trials in acute lymphoblastic leukemia (ALL) and pancreatic cancer. An investigator-sponsored Phase 2 (IST) trial evaluating the use of eryaspase in patients with ALL who developed hypersensitivity reactions to pegylated asparaginase recently reported positive results, based on which the Company intends to seek approval in the United States and potentially in other territories. The Company is also pursuing an investigator-sponsored Phase 1 clinical trial in first-line pancreatic cancer.

Eryaspase has received Fast Track Designation from the United States Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer and the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity reactions to E.coli-derived pegylated asparaginase. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL.

ERYTECH produces its product candidates for the treatment of patients in Europe at its GMP approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved drug.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the regulated market of Euronext in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indices.

For more information, please visit


Eric Soyer
Mathilde Bohin / Louis Victor Delouvrier
Investor Relations
Nicholas Merigeau
Media Relations

+33 4 78 74 44 38
[email protected]

+33 1 44 71 94 94
[email protected]

avant-garde Iinformation

This press release contains forward-looking statements, including, but not limited to, statements regarding the clinical development and regulatory plans of eryaspase, including the timing of a potential BLA submission to the FDA for treatment acute lymphoblastic leukemia, the Company’s ability to obtain regulatory approval for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity reactions to PEG-asparaginase, the Company’s ability to expand the field of indication of eryaspase, the Company’s ability to obtain additional financing under the OCABSA financing agreement or other financing attempts, and the Company’s anticipated cash flow. Some of these statements, forecasts and estimates can be recognized by the use of words such as, but not limited to, “believes”, “anticipates”, “expects”, “intends”, ” plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. These statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were believed to be reasonable at the time they were made, but which may or may not prove to be correct. Actual events are difficult to predict and may depend on factors beyond ERYTECH’s control. There can be no assurance with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or prove to be commercially successful. Accordingly, actual results and timing may differ materially from any anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. A more detailed description of these risks, uncertainties and other risks can be found in the regulatory documents filed by the Company with the Autorité des marchés financiers (AMF), the documents and reports of the Securities and Exchange Commission (SEC) of the Company, including in the Company’s 2020 Information Document. Universal Registration filed with the AMF on March 8, 2021 and in the Company’s annual report on Form 20-F filed with the SEC on March 8, 2021 and in future Company filings and reports. Given these uncertainties, no representation is made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Further, forward-looking statements, forecasts and estimates speak only as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update such forward-looking statements, forecasts or estimates to reflect any change in ERYTECH’s expectations in this regard, or any change in events, conditions or circumstances on which such statement, forecast or estimate is based. , except to the extent required by law. Additionally, the COVID-19 pandemic and associated containment efforts have had a severe negative impact on the economy, the severity and duration of which are uncertain. Government stabilization efforts will only partially mitigate the consequences. The extent and duration of the impact on the Company’s business and operations are highly uncertain, and such impact includes effects on its clinical trial operations and supply chain. Factors that will influence the impact on the Company’s business and operations include the duration and extent of the pandemic, the extent of containment and mitigation measures imposed or recommended, and the general economic consequences of the pandemic. . The pandemic could have a material adverse effect on the Company’s business, operations and financial results for an extended period.

  • PR_ERYTECH_Presentation ERCS_04422_EN

Comments are closed.